



PTO/SB/08a (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/849,039		
		Filing Date	May 20, 2004		
		First Named Inventor	DALTON, James T.		
		Art Unit	1621		
		Examiner Name	KUMAR, Shailendra		
Sheet	1	of	4	Attorney Docket Number	P-8235-US14

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
S	A	09/935,044	08/23/2001	Dalton et al.	
	B	09/935,045	08/23/2001	Dalton et al.	
	C	09/644,970	08/2/2000	Dalton et al.	
	D	6,019,957	02/01/2000	Miller, et al.	
	E	6,071,957	06/06/2000	Miller, et al.	
	F	6,160,011	12/12/2000	Miller, et al.	
	G	4,636,505	01/13/1987	Tucker	
	H	4,880,839	11/14/1989	Tucker	
	I	4,465,507	08/14/1984	Konno, et al.	
	J	3,875,229	04/01/1975	Gold	
	K	4,139,638	02/13/1979	Neri, et al.	
	L	4,191,775	03/04/1980	Glen	
	M	4,239,776	12/16/1980	Glen, et al.	
	N	4,386,080	05/31/1983	Crossley, et al.	
	O	4,282,218	08/04/1981	Glen, et al.	
V	P	5,609,849	03/11/1997	Kung	
	Q	5,162,504	11/10/1992	Horoszewicz	
	R	5,656,651	08/12/1997	Sovak, et al.	
	S	6,838,484	01-2005	Steiner, et al	
	T	6,569,896	05-2003	Dalton, et al	
	U	6,998,500	02-2006	Dalton, et al	
	V	7,026,500	04-2006	Dalton, et al	

Examiner Signature	J. Kumar	Date Considered	7/30/07
-----------------------	----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/849,039
		Filing Date	May 20, 2004
		First Named Inventor	DALTON, James T.
		Art Unit	1621
		Examiner Name	KUMAR, Shailendra
Sheet	2	of	4
		Attorney Docket Number	P-5235-US14

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
fe	W	WO98/53826	12/03/1998	Dalton et al.		<input type="checkbox"/>
	X	EP0 100 172	02/08/1984	Tucker		<input type="checkbox"/>
	Y	EP0 040 932	02/12/1981	Crossley et al.		<input type="checkbox"/>
	z	WO95/19770	07/27/1995	Gray		<input type="checkbox"/>
fe	AA	EP 0253503	12/11/1991	Tucker		<input type="checkbox"/>

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
fe	BB	WO 02 00617	01-03-2002	Bristol Myers Squibb		<input type="checkbox"/>
	CC	WO 01 27622	04-19-2001	Bristol Myers Squibb		<input type="checkbox"/>
	DD	WO 01 28990	04-26-2001	Nobex Corporation		<input type="checkbox"/>
	EE	WO 01 34563	05-17-2001	Nobex Corporation		<input type="checkbox"/>
	FF	WO 98 05962	02-12-1998	Panvera Corporation		<input type="checkbox"/>
	GG	EP 000 2892	02-06-1985	Imperial Chemical Indust.		<input type="checkbox"/>
	HH	JP 52-128329	10-27-1977	Teikoku Hormone Mfg.		<input type="checkbox"/>
	II	JP 54-63047	12-16-1980	Glen, et al		<input type="checkbox"/>
	JJ	GB 1360001	03-16-1970	Neri, et al		<input type="checkbox"/>
	KK	WO 95 19770	07-25-1995	Sepracor Inc.		<input type="checkbox"/>
	LL	WO 02 016310	02-28-2002	Dalton, et al		<input type="checkbox"/>
	MM	WO 98 55153	12-10-1998	Dalton, et al		<input type="checkbox"/>
	NN	WO 03049675	06-19-2003	GTX Inc.		<input type="checkbox"/>
fe	OO	WO 03065992	08-14-2003	GTX Inc.		<input type="checkbox"/>

Examiner Signature	J. Kumar	Date Considered	7/30/07
-----------------------	----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/849,039</td> </tr> <tr> <td>Filing Date</td> <td>May 20, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>DALTON, James T.</td> </tr> <tr> <td>Art Unit</td> <td>1621</td> </tr> <tr> <td>Examiner Name</td> <td>KUMAR, Shailendra</td> </tr> <tr> <td>Attorney Docket Number</td> <td>P-5236-US14</td> </tr> </table>		Application Number	10/849,039	Filing Date	May 20, 2004	First Named Inventor	DALTON, James T.	Art Unit	1621	Examiner Name	KUMAR, Shailendra	Attorney Docket Number	P-5236-US14
Application Number	10/849,039														
Filing Date	May 20, 2004														
First Named Inventor	DALTON, James T.														
Art Unit	1621														
Examiner Name	KUMAR, Shailendra														
Attorney Docket Number	P-5236-US14														
Sheet	3	of	4												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SC	PP	Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, "Resolution of the Nonsteroidal Antiandrogen - 4'-Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer "	<input type="checkbox"/>
	QQ	D. McKillop, et al., "Enantioselective metabolism and pharmacokinetics of Casodex in the male rat", Xenobiotica, 1995, Vol. 25, No. 6, 623-634.	<input type="checkbox"/>
	RR	Leonid Kirkovsky, et al., "[¹²⁵ I]-Radiolabeled Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer", Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sept. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163	<input type="checkbox"/>
	SS	David T. Baird and Anna F. Glasier, "Hormonal Contraception - Drug Therapy", The New England Journal of Medicine, May 27, 1993, pp. 1543 - 1549	<input type="checkbox"/>
	TT	F.C. W. Wu, "Male Contraception: Current Status and Future Prospects", Clinical Endocrinology, (1988), 29, pp. 443-465	<input type="checkbox"/>
	UU	Carl Djerassi and S.P. Leibo, "A new look at male contraception", Nature, Vol. 370, pp. 11-12	<input type="checkbox"/>
	VV	World Health Organisation Task Force on Methods for the Regulation of Male Fertility, "Contraceptive efficacy of testosterone-induced azoospermia in normal men", The Lancet, Vol. 336, October 20, 1990, pp. 955-959 and 1517-1518	<input type="checkbox"/>
	WW	C. G. Francisco, et al., "Long-acting contraceptive agents: testosterone esters of unsaturated acids", Steroids, January 1990, vol. 55, Butterworths	<input type="checkbox"/>
	XX	John M. Hoberman and Charles E. Yesalis, "The History of Synthetic Testosterone", Scientific American, February 1995, pp. 76-81.	<input type="checkbox"/>
	YY	Leonid Kirkovsky, et al., "Approaches to Irreversible non-steroidal chiral antiandrogens", Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/S1st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995	<input type="checkbox"/>
	ZZ	David J. Handelsman, "Bridging the gender gap in contraception: another hurdle cleared" The Medical Journal of Australia, Vol. 154, February 18, 1996, pp. 230-233.	<input type="checkbox"/>

Examiner Signature	S. Kumar	Date Considered	7/30/07
--------------------	----------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/849,039
		Filing Date	May 20, 2004
		First Named Inventor	DALTON, James T.
		Art Unit	1621
(use as many sheets as necessary)		Examiner Name	KUMAR, Shailendra
Sheet	4	of	4
		Attorney Docket Number	P-5235-US14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S. Kumar	a	Edwards JP, Higuchi RI, Winn DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg. Med. Chem. Lett., 9: 1003, 1999.	<input type="checkbox"/>
	b	Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009, 1999.	<input type="checkbox"/>
	c	Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diaryl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett., 9:1335,1999.	<input type="checkbox"/>
	d	Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, and Jones TK. Discovery of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]quinoline (LG121071). J. Med. Chem., 42: 210, 1999.	<input type="checkbox"/>
	e	Rosen J, Day A, Jones TK, Jones ET, Nadzan AM, and Stein RB. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem., 38: 4855, 1995.	<input type="checkbox"/>
	f	Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Commun., 244(1):1-4, 1998.	<input type="checkbox"/>
	g	Edwards JP, West SJ, Pooley CLF, Marschke KB, Farmer LJ, and Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2-(1H)-Pyrololidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 8: 745, 1998.	<input type="checkbox"/>
	h	Ellison, et al "High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands." Abstracts of Papers, 223 rd ACS National Meeting, Orlando Fla. U.S. 2002	<input type="checkbox"/>
	i	Berger, et al "Concepts and Limitations in the Application of Radiolabeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate." Invest. Urol. 1975 1391, 10-16	<input type="checkbox"/>
	j	Narayanan, et al "Steroidal Androgens and Nonsteroidal, Tissue Selective Androgen Receptor Modulators (SARM) Regulate Androgen Receptor Function Through Distinct Genomic and Non-Genomic Signaling Pathways." The Endocrine Society - Programs and Abstracts - 89 th Annual Meeting - Paper P1-595.	<input type="checkbox"/>
	k	Yepuru, et al "AN Androgen Receptor-b Specific Selective Estrogen Receptor Modulator (SERM) Inhibits the Growth of the Prostate Cancer Cells and Stromal-Epithelial Tumor Xenograft." The Endocrine Society - Programs and Abstracts - 89 th Annual Meeting - Paper OR6-3.	<input type="checkbox"/>
l	Dalton, et al "Therapeutic Promise of Selective Androgen Receptor Modulators (SARMs): Preclinical and Clinical Proof-of-Concept Studies." The Endocrine Society - Programs and Abstracts - 89 th Annual Meeting - Paper S41-2.	<input type="checkbox"/>	

Examiner Signature	S. Kumar	Date Considered	7/30/07
--------------------	----------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.